Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.

Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.

As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.

Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.

AI-native operating systems present new capabilities to improve pharma supply chain operations.

Cencora's Gregg Gorniak on where DSCSA trading partners find shared value in compliance investment, and where that alignment breaks down.

Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.

Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.